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Abstract
Objective This study was conducted to compare the relative,
clinical intraocular dose distribution for palladium-103
(103Pd) versus iodine-125 (125I) ophthalmic plaque radiation
therapy.
Methods Preoperative comparative radiation dosimetry was
performed to evaluate 319 consecutive uveal melanomas
treated between 2006 and 2012.
Results There were 68 (21.3 %) anterior (iris and/or ciliary
body) and 251 (78.7 %) choroidal melanomas examined in
this study. According to AJCC staging, 7th edition, 146
(45.8 %) were T1, 126 (39.5 %) T2, 40 (12.5 %) T3, and 7
(2.2 %) T4. All were prescribed an equivalent tumor-apex
dose. When compared to 125I, 103Pd was associated with a
mean 41.9 % lower radiation dose to the opposite eye wall
(p<0.001), 12.7 % to the lens center (p<0.001), 7.5 % to the
optic disc (p=0.008), and a 3.8 % decrease to the fovea (p=
0.034). However, subgroup analysis of smaller (T1-staged)
tumors showed greater dose reductions to normal ocular
structures compared to larger (T4-staged) tumors. Tumor
and therefore plaque location also affected intraocular dose
distribution. For example, palladium-103-related dose reduc-
tions to the fovea, optic nerve, and opposite eye wall were
significantly greater for iris and ciliary body tumors compared
to posterior choroidal melanomas (p<0.001). After compara-
tive dosimetry, 98.7 % (n=315/319) were treated with 103Pd.
Conclusion Preoperative comparative radiation dosimetry
was performed for a large cohort of patients with uveal mela-
noma. It influenced radionuclide selection, offered an opportu-
nity for radiation sparing of critical vision-related intraocular
structures, and typically increased radiation within the tumors.
Keywords Brachytherapy . Plaque . Palladium-103 .
Iodine-125 . Choroidal melanoma
Introduction
Complications of plaque brachytherapy have been related to
dose to normal ocular structures [1–5]. However, little has
been written about methods to diminish unnecessary irradia-
tion outside the targeted treatment volume [6–10, 5, 11].
In 1990, the first preclinical pilot studies used computer
simulations and then thin layer dosimeter (TLD)-laden frozen
eye bank eyes to compare 103Pd and 125I ocular dose distribu-
tions [8]. For an equivalent tumor target dose, the less ener-
getic (21 keV) 103Pd-photons were more quickly absorbed
than those from the (28 keV) 125I plaques within the eye and
vitreous before it reached the episcleral dosimeters. In clinical
practice, it was reasonable to assume that when outside the
targeted volume (beneath the plaque), there would be relative
103Pd-related dose reductions to the macula, optic nerve, and
lens. In 2009, the clinical results of 400 cases of choroidal
melanoma treated by 103Pd ophthalmic plaque therapy dem-
onstrated improved local control and visual acuity outcomes
compared to other series using 125I [12].
In 2011, the American Association of Physicists in
Medicine (AAPM) Task Group-129 (TG-129) examined the
relative ocular dose distributions of 125I versus 103Pd plaque
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treatment for a single moderately sized T1 tumor and found
relative dose advantages with the use of 103Pd [11]. In a
second publ ica t ion together wi th the American
Brachytherapy Society (ABS), the AAPM TG-129 suggested
that comparative preoperative dosimetry could improve clin-
ical care [13]. Most recently, the ABS Ophthalmic Oncology
Task Force guidelines reached consensus that a pretreatment
comparison of available sources be employed prior to plaque
therapy [14].
Since 2006, at The New York Eye Cancer Center and
affiliated hospitals, we have routinely compared 125I to
103Pd prior to ophthalmic plaque brachytherapy. Utilizing
data from those evaluations, we present the largest clin-
ical case series of preoperative intraocular dosimetric
comparisons for ophthalmic plaque brachytherapy for
uveal melanoma.
Methods
Clinical evaluation and diagnosis
Preoperative comparative (103Pd versus 125I) dosimetry calcu-
lations were performed for 319 uveal melanoma patients
treated between 2006 and 2012. Patients were diagnosed with
uveal melanoma by clinical examination. A combination of
ophthalmoscopy, fluorescein angiography, transillumination,
and B-scan ultrasound were used to determine the tumor’s
basal dimensions and apical height. Anterior uveal tumors
(defined as iris and ciliary body melanomas) were assessed
by slit-lamp biomicroscopy, gonioscopy, high-frequency ul-
trasound imaging and photography. Our methods of diagnosis
are consistent with that described in the ABS/AAPM TG-129
report [13]. All tumors were T-staged according to the
American Joint Committee on Cancer (AJCC) System, 7th
edition [15–18].
Dosimetric calculations and treatment
Preoperative dosimetry calculations for 103Pd and 125I were
performed to be comparable to the COMS protocol and
followed the current recommendations of the American
Association of Physicists in Medicine Task Group-43 (AAPM
TG-43) [19, 13, 11, 20–22]. Thus, seeds were calculated as
approximate isotropic point sources with no corrections for
anisotropy. No attenuation was attributed to the acrylic fixa-
tive or for the gold plaque sidewalls. The backscatter effects
from the plaque’s posterior wall were discounted. A 103Pd
specific dose rate constant of 0.686 cGy/h/mCi was used. The
radial dose function was obtained from published data
[23–25]. The prescription point was the tumor’s apex, consis-
tent with the 2003 and most current ABS recommendations
[22, 14].
We chose to analyze four points along the central axis of
the plaque: inner sclera, 5-mm axial depth, opposite retina,
and the tumor’s apex. Due to their importance for visual
acuity, additional intraocular locations included: the fovea,
optic disc, and lens.
Statistical analysis
Comparison of the 103Pd and 125I ophthalmic plaque doses
was computed using the Mann–Whitney U test. A confidence
interval (CI) of 95 % was generated from the statistical anal-
ysis. In comparison of 103Pd and 125I ophthalmic plaque
doses, a P value<0.05 was considered statistically significant.
Results
Tumor characteristics
There were 319 uveal melanomas evaluated by comparative
dosimetry between 2006 and 2012. They had a mean 4.0 mm
apical height (range 1.8–14.2) and a mean 9.9 mm basal
dimension (range 1.8–21). The majority were AJCC T1 and
T2 stages at 45.8 % and 39.5%, respectively (Table 1). This is
comprised of iris or ciliary body (n=68/319, 21.3 %), but
majority were choroidal melanomas (n=251/319, 78.7 %).
Comparative dosimetry
Central axis dose
All treatment plans were analyzed for the relative dose depo-
sition along the central axis of the plaque (inner sclera, 5 mm
and opposite eye wall). By definition, the tumor’s apex re-
ceived a mean equivalent dose for both radionuclides (Fig. 1).
However, the use of 103Pd (versus 125I) was associated with a
mean 10.4 % increase in dose to the inner scleral base (p=
0.040) and a 1.1% increase at 5-mm axial depth (p=0.031) for
that equivalent tumor-apex dose. Therefore, the use of 103Pd
was found to steepen the dose gradient within the tumor.
Specifically, for an equivalent tumor-apex dose, the use of
Table 1 Melanoma characteristics and location
Percentages (n)*
Tumor stage T1 45.8 % (146)
T2 39.5 % (126)
T3 12.5 % (40)
T4 2.2 % (7)
Tumor location Anterior (iris and ciliary body) 21.3 % (68)
Choroid 78.7 % (251)
n number of patients
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103Pd increased the mean radiation dose within the tumor by
mean 7.6 % (157.9 versus 146.7 Gy) compared to 125I.
Then as the lower energy 103Pd photons continue along the
central axis across the eye, they were more rapidly absorbed
(in the vitreous) before it reached the opposite eye wall
(Fig. 1). At that data point, the use of 103Pd resulted in a
41.9 % reduction of radiation dose (p<0.001).
Dose to critical intraocular structures
Vision retention is related to the function of certain critical
radiosensitive intraocular structures. Therefore, we compared
the radiation dose to the natural lens center, optic nerve, and
fovea. Depending on the intraocular location of the tumor (and
therefore the plaque), these critical structures can be located
either within or outside the target volume [26]. In this series,
the use of 103Pd (versus 125I) demonstrated overall mean
reductions to these critical intraocular structures (Table 2).
Specifically, the optic disc and fovea showed a mean 103Pd-
related reduction of 7.5 % (p=0.008) and 3.8 % (p=0.034),
respectively. The lens center showed a greater mean 103Pd-
related radiation dose reduction of 12.7 % (p<0.001).
Comparing anterior versus posterior tumor location
The subgroups of 68 anterior (iris and ciliary body) and 251
choroidal melanomas had relatively equivalent mean apical
heights (3.8 versus 4.1 mm, respectively). Thus, both groups
generally resulted in 103Pd-related increased radiation dose to
the subjacent inner sclera and to the 5-mm axial depth (Fig. 1).
Similarly, the use of 103Pd reduced the radiation dose to the
opposite retina by 41.5 % (p<0.001) and 43.1 % (p<0.001)
for anterior and posterior melanomas, respectively.
However, this subgroup analysis (anterior versus posteriorly
located tumors) also revealed that the tumors’ relative distance
to the lens, fovea, and optic disc was markedly different
(Fig. 2). Specifically, anterior tumors were in closer proximity
to the natural lens and farther from the macular fovea and optic
disc. Conversely, posterior tumors were in closer proximity to
the fovea and optic disc. These differences were found to affect
the relative dose distributions for 103Pd versus 125I plaques.
Specifically, in treatment of anterior tumors, 103Pd offered
relative dose reductions of a mean 4.7 % (p=0.285) to the
relatively close lens. However, in treatment of posteriorly lo-
cated melanomas, the use of 103Pd reduced the lens dose by
23.0 % (p<0.001). Similarly, in evaluation of the fovea and
optic disc, the subset of anteriorly located tumors revealed
mean 103Pd-related dose reductions of 16.9 % (p<0.001) to
the fovea and 20.0 % (p<0.001) to the optic disc. However, by
comparative dosimetry for the subset of posteriorly located
choroidal melanomas, mean103Pd-related dose reductions were
3.1 % (p=0.175) to the fovea and 6.5 % (p=0.040) to the optic
nerve. This analysis revealed that 103Pd typically reduced the
mean dose to the lens, fovea, and optic disc. However, the
magnitude of that difference was dependent on distance.
AJCC T stage tumor comparison
Dosimetry of 103Pd versus 125I was also analyzed by AJCC T
staging (Table 3). The most significant differences were noted
Fig. 1 Dose gradient along the
central axis of the plaque
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between the relatively small T1 and the large T4 melanomas.
For example, axial dosimetry for T1-staged tumors (n=146)
and T4-staged tumors (n=7) revealed that 103Pd was associ-
ated with a mean increase in dose to the inner sclera of 4.5 %
(p=0.066) versus 32.2 % (p=0.208), respectively. This shows
that while all tumors received a higher mean scleral dose using
103Pd, the dose difference increased with tumor size.
Similarly, the radiation dose to a 5-mm axial depth demon-
strated a decrease of 6.6 % with 103Pd for the relatively short
T1 tumors and an increase of 24.2 % for T4 tumors (Fig. 3).
Once the radiation extended beyond the equivalent tumor-
apex prescription dose, 103Pd radiation was absorbed by the
vitreous before reaching the opposite eye wall. Dose to this data
point was also affected by tumor height. For example, in treat-
ment of taller tumors, there was less intervening vitreous or
distance to the opposite eye wall. Thus, 103Pd-related mean dose
reductions to the opposite eye wall were 45.9 % (p<0.001) for
T1 tumors versus 29.9 % (p=0.208) for T4 tumors (Table 3).
However, all the important anatomical ocular structures (lens
center, optic disc, and fovea) demonstrated mean dose reduc-
tion with 103Pd versus 125I for T1 to T3 tumors (Fig. 3). Here,
comparative dosimetry revealed that the use of 103Pd decreased
the mean dose to the opposite eye wall, while 103Pd increased
the mean dose to the lens, optic disc, and fovea in T4-staged
uveal melanomas (Fig. 3). Detailed subset analysis demonstrat-
ed that the use of 103Pd would increase the dose (for T4-staged
tumors) to the lens and fovea in three eyes (n=3/7, 43%) and to
the optic disc in two eyes (n=2/7, 29 %). No eye with a tumor
in the T4 subset exhibited a relative increase to all three ocular
structures (optic disc, fovea, and lens) using 103Pd.
Patients treated with 125I plaques
There were 315 patients (98.7 %) who received 103Pd plaque
therapy and four patients who received 125I plaque therapy.
The four tumors treated with 125I had a mean 11.7 mm apical
height (range 8.2 to 14.2) and a mean 16.1 mm basal dimen-
sion (range 13.9–17.9). The distance from the tumor edge to
the macula and optic disk ranged from 0 to 3.4 mm and from 0
to 3.9 mm, respectively. Of these four tumors, two were T3
and two were T4 tumors. In those four 125I-treated eyes, the
lens received an increased 125I dose of 12.6 % relative to that
of 103Pd. However, it was the mean 125I-related dose reduction
at the optic disc and fovea (10.5 and 16.0 %, respectively) that
was the main reason for using 125I. Overall, three patients
received lower optic disc dose due to the use of 125I and all
four patients received lower fovea dose with 125I.
Discussion
Comparative clinical dosimetry was used to analyze intraoc-
ular dose distribution prior to radiation therapy for 319 uveal
melanomas. Specifically, lower energy 103Pd was compared to
relatively higher energy 125I seeds for ophthalmic plaque
therapy. Evaluations along the central axis of the plaque
revealed that the scleral dose was higher utilizing 103Pd.
Therefore, with an equivalent planned apex prescription, the
use of 103Pd increased the mean tumor dose. In addition, the
opposite eye wall was both the farthest from the plaque and
best represented organ dose. Here, the use of 103Pd was
associated with an overall reduction of 41.9 % (p<0.001). In
comparison of critical targets for vision preservation, there
were modest overall 103Pd-related dose reductions to the lens,
optic disc, and fovea. While subset analysis of anteriorly
located uveal melanomas revealed significantly greater
103Pd-related sparing of the optic disc and fovea, dosimetry
for the posterior choroidal melanomas revealed more signifi-
cant mean dose reductions to the lens.
Tumor size also influenced the intraocular dose distribution.
In comparison of 103Pd versus 125I, increased T staging as per
AJCC, 7th edition, was associated with relatively more tumor
irradiation with 103Pd. For example, from T1 to T4, the mean
percent increase in dose to the inner sclera rose from 4.5 % (p=
0.066), 8.4 % (p=0.131), 20.3 % (p=0.051), and 32.2 % (p=
0.208), respectively. Conversely, the mean percent decrease in
dose to the opposite retina provided by 103Pd relative to 125I
trended to diminish as the tumors get larger, T1 45.92 %
(p<0.001), T2 47.1 % (p<0.001), T3 30.0 % (p<0.001), and
T4 29.9 % (p=0.208). As their edges were more likely to be in
Fig. 2 Tumor location affects
distance to critical normal ocular
structures
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close proximity to the lens center, optic disc, and fovea, higher T-
staged (larger uveal melanomas) exhibited smaller percent dif-
ferences between radionuclides. In these cases, it was not un-
common to find the calculated dose to these critical ocular
structures beyond published tolerances. In addition, our decisions
to use 103Pd were related to dose savings to the opposite eye wall
in an effort to diminish organ dose.
The majority of tumors were treated with 103Pd, but 1.3 %
tumors (n=4/319) received 125I. In general, the decision to use
125I was influenced by the higher mean 103Pd dose at the optic
disc (10.5%) and fovea (16.0%). The increased 103Pd dose at the
optic disc and foveawas affected by the large tumor apical height
and proximity of the optic disc and fovea to the tumor edge.
The limitations of this study include the following: it is
from a single center, it was retrospective, and there was a small
sample size of T4 tumors. Furthermore, the dosimetry calcu-
lations in this series assumed homogeneous water-equivalent
tissues consistent with TG-43. The 2012 AAPM and ABS
TG-129 recommended computing both homogenous and het-
erogeneous dose calculations as part of the preoperative
plaque planning [13]. They noted that there can be large
variations in doses between the two methods and that plaques
often have heterogeneous material within that can affect dose
calculations to normal intraocular structures [13]. Dosimetric
calculations in this study also neglected anisotropy correction
recommended by TG-43 to be in agreement with COMS
practice [21, 23, 11]. As there are no universally accepted
clinical dosimetry methods used at multiple ophthalmic
brachytherapy centers, we present our findings as relatively
equivalent to standard clinical practice during our period of
recruitment. Though we recognize that different dosimetry
methods may change the absolute numbers, there is no reason
to believe they would change the dose distribution trends
revealed by this work.
Conclusion
This study demonstrates that pretreatment comparative dosime-
try can be used to evaluate the intraocular distribution of radiation
and aid radionuclide selection. Our study revealed that when
comparing 125I versus 103Pd plaque therapy for uveal melanoma,
both tumor size and location affected the relative dose to critical
normal intraocular structures. In 319 patients, the use of 103Pd
resulted in a trend toward increased dose within the tumor target
volume and decreased dose to most normal ocular structures.
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